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In the last years, the “one target, one drug” paradigm that has traditionally dominated drug
discovery has been deeply challenged by the evidence that small molecules interact simultaneously
with multiple targets, a phenomenon known as polypharmacology. Today, polypharmacology is
recognized as a new valuable opportunity for drug discovery and development. It is now well
established that drug molecules typically bind to several targets, and that their efficacy and safety
is mostly dependent on their polypharmacological profile (Jalencas and Mestres, 2012; Peters,
2013; Anighoro et al., 2014). Indeed, one of the most common reasons for terminating a drug
discovery program has been promiscuity or lack of selectivity of the developed compounds. This
leads to important considerations regarding the polypharmacology inherent in chemical structures
and its possible exploitation for drug discovery. First, side effects caused by drug binding to
unwanted off-targets (adverse polypharmacology) should be identified as early as possible in the
drug discovery pipeline. Second, potential synergistic effects arising from hitting multiple targets
(beneficial polypharmacology) should be taken into consideration and thoroughly incorporated
in the drug design strategy. Third, polypharmacological approaches have the potential to redirect
stalled drug discovery projects and to reposition valuable hits or leads (drug repositioning). Finally,
prediction of polypharmacological profiles can be used to uncover new macromolecular targets
for already known or new developing drugs (target identification and deconvolution). In all these
areas, computational polypharmacology is gaining a foothold in drug discovery, as witnessed by the
increasing number of publications reporting theoretical approaches and methods specifically put
forward to address these needs.
State-of-the-art computational approaches offer the possibility to predict the activity profile of
ligands to a set of targets, thereby anticipating potential selectivity issues or discovering desired
multitarget activities early in the iterative design and optimization steps typical of a preclinical
drug discovery project. These approaches stem from 2D or 3D shape and chemical similarity,
pharmacophore analyses, target and binding site similarity assessment, docking methods,
bioinformatics, graph theory and modeling, machine-learning algorithms, and chemogenomics
(Figure 1). Broadly, these can be classified into statistical data analysis and bioinformatics, ligand-
based, and structure-based approaches, all of which are well documented in the literature (Csermely
et al., 2005; Boran and Iyengar, 2010; Bottegoni et al., 2012; Anighoro et al., 2014; Reddy et al.,
2014). One should note that ligand-based and structure-based strategies have specific advantages
and limitations. Structure-based methods use the information derived from knowledge of the
3D structure of proteins. These methods are applicable to identify ligands for a specific target
or set of targets of interest, for example by performing de-novo design or virtual screening of
large libraries of small molecules. In addition, they can be used to assess binding site structural
similarity and to profile protein-ligand interactions among sets of targets. Their application is
obviously limited to proteins with known crystal structure or to homology models derived from
highly homologous crystal structure templates. Moreover, structure-based results are influenced
by differences in conformations of binding site residues, which are generally difficult to predict.
Ligand-based approaches do not require crystal structures of the target proteins but rely on
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FIGURE 1 | Computational approaches useful for predicting
polypharmacology. Statistical data analysis and bioinformatics,
ligand-based, and structure-based approaches can be applied either
singularly or in combination, to take advantage of the peculiar features and
strengths of each approach. The lower part of the figure shows three different
proteins (A–C) interacting with the same ligand, and highlights that the final
pharmacological effect of the ligand is the result of synergistic effects arising
from interaction with all targets.
prior knowledge of biologically active ligands, therefore their
use is limited to targets for which ligands are known. Worth of
note is that in ligand-based methods the derived information is
necessarily dependent on the chemical structures of the classes of
compounds that have been thus far developed. As a consequence,
predicting polypharmacological profiles of ligands that are
too dissimilar to already synthesized classes of compounds
would be impossible. Overall, ligand-based and structure-based
methods appear to be applicable in conjunction to provide
more robust results (Anighoro et al., 2015). Such combination
offers the possibility to take advantage of the peculiar features
and strengths of each approach toward the obtainment of
possible candidates for polypharmacology, and appears to be
one promising way to go in future investigations. For example,
one risk of predicting polypharmacology by using only chemical
similarity principles is that inactive compounds can exhibit high
similarity with active molecules if they derive from a slight
modification of an active compound at some key position crucial
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for its interaction with the target. In this case such similarity
would lead to false positives. Likewise, false negatives can be
expected considering that not all of active compounds have
been identified for a given target. In these cases, structure-based
methods can help overcome these potential pitfalls by estimating
the steric and electrostatic complementarity of ligands with
the target binding sites. For example, structure-based docking
screenings of compounds that passed the desired chemical
similarity filters may be independently performed on two or
more biological targets of interest, and multi-target hits may
be identified from compounds located at the top of all ranked
lists. Finally, analysis of drug targets and drug-target associations
using a network approach may provide useful information to
highlight particularly interesting target combinations or chemical
modulators able to perturb the network at specific nodes of
disease-specific critical pathways (Csermely et al., 2013). In this
context, partial inhibition of a small number of targets can be
more efficient than the complete inhibition of a single target,
especially for complex and multifactorial diseases (Csermely
et al., 2005). This information can be used by ligand-based or
structure-based methods to direct the design and screening of
new drugs toward the desired set of multiple drug targets.
Polypharmacology has been mainly recognized within
members of the kinome and GPCRs families (Knight et al., 2010;
Jacobson et al., 2014). This is not surprising, considering that
binding sites within members of conserved and evolutionarily
related targets are generally conserved and thus prone to
multitarget inhibition. However, one should note that the
recognized specificity of a ligand or a series of ligands depends
heavily on how hard on- and off-targets have been investigated,
and this is surely the case for kinases and GPCRs, which have
been extensively explored. We are far from having the capacity to
perform an exhaustive biological profiling of ligands that enter
into drug discovery pipelines, but we can expect that the more
testing will be performed, the more off-targets and multitarget
activities will be seen also for targets genetically and structurally
unrelated to the primary intended target. In this respect, constant
improvement and implementation of compound and bioactivity
data deposited in publicly available databases will provide
access to an increasing number of high confidence bioactivity
annotations for larger sets of chemicals and therapeutic targets
(Hu and Bajorath, 2013). Overall, this information will be very
useful to computationally design multitarget ligands. In parallel,
improvement in hardware and software performance is making
it possible to handle an enormous amount of data, thus enabling
the generation and analysis of big data for polypharmacology in
a very cost- and time-effective way.
The rational design of molecules interacting with more than
one biological target becomes most challenging when these
targets are only distantly related or unrelated, i.e., when they
belong to different protein families. For example, the selectivity
of particularly interesting kinase inhibitors are usually profiled
against a large panel of kinases of the kinome, but they are
rarely screened against targets of other families due to limited
capacity of experimental in vitro testing. Considering that local
binding site similarities may be more important than global
structural similarity to determine polypharmacological activities,
especially when ligands are able to interact with key residues
of more than one target, this remains a critical point for the
development of multi-targeted drugs (Salentin et al., 2014).
Therefore, assessing local binding site similarities and comparing
protein-ligand interaction profiles, especially for distantly related
sets of targets and chemical classes of ligands, will be crucial
for predicting polypharmacology (both beneficial and harmful).
Significant improvements are also needed on how to select the
most relevant set of therapeutically important targets for a given
disease, a question that can benefit of the recent progresses of
proteomics and clinical molecular investigations on patients and
disease states.
Progresses in modeling protein-ligand interactions and in
quantitatively predicting free energies of binding of ligands to
target proteins will definitely contribute to successful design
of molecules with the desired polypharmacological profile. The
ongoing advances in docking methods such as improvement
of scoring functions and better treatment of receptor flexibility
are playing an important role to meet this goal. Importantly,
several free-energy based approaches, with different theoretical
backgrounds and at different levels of approximation, have been
proposed to rescore docking results in order to increase the
accuracy of binding affinity predictions (Parenti and Rastelli,
2012). Considering that the affinity of a ligand for a target
protein reflects the 1G of binding, any further improvement
in our ability to accurately predict binding free energies will be
important to design multi-target drug candidates.
Combining computational design and chemical synthesis of
libraries of multi-target ligands provides another means to more
effectively obtain bioactive compounds with the desired on- and
off-target binding. For example, Reutlinger et al. very recently
described the development and application of a computational
molecular de novo method for designing combinatorial libraries
that exhibit an accurately predicted bioactivity profile, obtaining
nanomolar multitarget ligands modulating the dopamine D4 and
sigma-1 receptors (Reutlinger et al., 2014). In another study,
Rodrigues et al. showed that the combination of machine-
learning methods with automated chemical synthesis and fast
bioassay turnover enabled the generation of small molecules with
the desired polypharmacology (Rodrigues et al., 2015). These
investigations suggest that a combination of the two approaches
may be suitable for rapidly obtaining hits and leads with the
desired target engagement.
Finally, a thorough understanding of drug-target network
relationships and target-disease associations is key not only to
provide more effective and safer drugs, but also to uncover
specific target combinations that may provide synergistic effects
and/or benefits for mitigating or bypassing drug resistance. In
other words, selecting the “right” combination of targets for
a specific disease will probably be a major key to success,
and this should be given full consideration by focusing
computational experiments on target combinations suggested
by clinical and/or molecular biology investigations. So far,
given the high number of cellular targets and our limited
ability to understand their interplay in disease states, most
biologically active small molecules are likely to bind several
targets and/or to activate or suppress alternate pathways or
Frontiers in Pharmacology | www.frontiersin.org 3 July 2015 | Volume 6 | Article 157
Rastelli and Pinzi Computational polypharmacology comes of age
targets. Network models are providing useful information to
analyze the interconnection of pathways and targets relevant
to human diseases, and their relation with chemical compound
networks (Schadt et al., 2009). However, the more the pathways
and mechanisms of disease (especially multifactorial and
complex diseases) will be understood at the molecular level,
the more the polypharmacological networks can be exploited
with computational methods to obtain safer and potent drugs
able to modulate the desired on- and off-target activities. The
recent successes in de novo predicting drug polypharmacology
and the raising number of computational strategies and
frameworks developed at this purpose testify that computational
polypharmacology has come of age and will play an increasingly
important role in drug discovery. The combination of different
approaches and expertise (experimental and computational) will
likely be key to success.
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